The prognosis and management of inactive HBV carriers

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B e antigen (HBeAg)-negative patients with antibodies against HBeAg (anti-HBe) are the most common HBV carriers globally.
• Distinguishing inactive carriers (ICs) from HBeAg-negative chronic hepatitis is crucial due to differing prognoses.
• ICs are defined by persistently normal alanine aminotransferase (ALT) and low HBV DNA levels (<2000 IU/ml).

Purpose of the Study:

• To clarify the diagnostic criteria and clinical management of inactive HBV carriers.
• To highlight the favorable prognosis of ICs and the limited need for antiviral therapy.
• To emphasize the importance of monitoring for HBV reactivation in ICs, particularly those undergoing immunosuppression.

Main Methods:

• Confirmed IC diagnosis requires at least 1 year of quarterly ALT and HBV DNA measurements.
• A single measurement of HBsAg <1000 IU/ml and HBV DNA <2000 IU/ml strongly predicts IC status.
• Liver stiffness <5 kPa on Fibroscan indicates minimal histological liver damage in ICs.

Main Results:

• ICs have a favorable prognosis with minimal liver disease and rare hepatocellular carcinoma (HCC) development, especially in Caucasian populations.
• Spontaneous hepatitis B surface antigen (HBsAg) loss occurs in 1-1.9% of ICs annually.
• Antiviral treatment is generally not indicated for ICs without cofactors for liver damage (alcohol, obesity, co-infections).

Conclusions:

• Inactive HBV carriers represent a distinct subgroup with a favorable prognosis, requiring long-term surveillance rather than antiviral treatment.
• Monitoring ALT, HBV DNA, and HBsAg levels annually is recommended for IC management.
• Prophylactic antiviral therapy is crucial for ICs undergoing immunosuppressive treatment to prevent HBV reactivation.